Plasma osteopontin level as a diagnostic marker of hepatocellular carcinoma in patients with radiological evidence of focal hepatic lesions

Tumori

Volumn 99, Issue 1, 2013, Pages 100-107

  Khalil, Ashraf ^a,d   Elgedawy, Jamalat ^a   Faramawi, Mohammed F ^a,c   Elfert, Ashraf ^a   Salama, Ibrahim ^a   Abbass, Ahmed ^a   Elsaid, Hala ^a   Elsebaai, Hatem ^b  

^a MENOUFIA UNIVERSITY   (Egypt)

^b MENOUFIA UNIVERSITY   (Egypt)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

AFP; Focal hepatic lesion; Hepatocellular carcinoma; Liver cirrhosis; Osteopontin

Indexed keywords

ALPHA FETOPROTEIN; OSTEOPONTIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; RADIOGRAPHY; SENSITIVITY AND SPECIFICITY; TURKEY (REPUBLIC);

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TURKEY;

MLCS; MLOWN;

EID: 84878119360     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161309900117     Document Type: Article

References (54)

1. Venook AP, Papandreou C, Furuse J, de Guevara LL: The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist, 15 (Suppl 4): 5-13, 2010.
2. el-Zayadi AR, Badran HM, Barakat EM, Attia Mel D, Shawky S, Mohamed MK, Selim O, Saeid A: Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol, 11: 5193-5198, 2005.
3. Lehman EM, Wilson ML: Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. Int J Cancer, 124: 690-697, 2009.
4. Sanyal AJ, Yoon SK, Lencioni R: The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist, 15 (Suppl 4): 14-22, 2010.
5. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132: 2557-2576, 2007.
6. Elsayes KM, Narra VR, Yin Y, Mukundan G, Lammle M, Brown JJ: Focal hepatic lesions: diagnostic value of enhancement pattern approach with contrast-enhanced 3D gradient-echo MR imaging. Radiographics, 25: 1299-1320, 2005.
7. Huang GT, Sheu JC, Yang PM, Lee HS, Wang TH, Chen DS: Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma - a study based on 420 patients. J Hepatol, 25: 334-338, 1996.
8. Durand F, Regimbeau JM, Belghiti J, Sauvanet A, Vilgrain V, Terris B, Moutardier V, Farges O, Valla D: Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol, 35: 254-258, 2001.
9. Daniele B, Bencivenga A, Megna AS, Tinessa V: Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology, 127: S108-112, 2004.
10. Tan CH, Low SC, Thng CH: APASL and AASLD consensus guidelines on imaging diagnosis of hepatocellular carcinoma: a review. Int J Hepatol, 2011: 519783, 2011.
11. Bae JS, Park SJ, Park KB, Paik SY, Ryu JK, Choi CK, Hwang TJ: Acute exacerbation of hepatitis in liver cirrhosis with very high levels of alpha-fetoprotein but no occurrence of hepatocellular carcinoma. Korean J Intern Med, 20: 80-85, 2005.
12. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM: Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med, 61: 317-328, 2010.
13. Stefaniuk P, Cianciara J, Wiercinska-Drapalo A: Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol, 16: 418-424, 2010.
14. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M: Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology, 137: 110-118, 2009.
15. Senger DR, Wirth DF, Hynes RO: Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell, 16: 885-893, 1979.
16. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW: Osteopontin: possible role in prostate cancer progression. Clin Cancer Res, 5: 2271-2277, 1999.
17. Angelucci A, Festuccia C, Gravina GL, Muzi P, Bonghi L, Vicentini C, Bologna M: Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. Prostate, 59: 157-166, 2004.
18. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR: Osteopontin expression and distribution in human carcinomas. Am J Pathol, 145: 610-623, 1994.
19. Weber GF: The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta, 1552: 61-85, 2001.
20. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, Hruban RH, Yeo CJ, Goggins M: Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev, 13: 487-491, 2004.
21. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res, 7: 4060-4066, 2001.
22. Saeki Y, Mima T, Ishii T, Ogata A, Kobayashi H, Ohshima S, Ishida T, Tabunoki Y, Kitayama H, Mizuki M, Katada Y, Asaoku H, Kitano M, Nishimoto N, Yoshizaki K, Maeda M, Kon S, Kinoshita N, Uede T, Kawase I: Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br J Haematol, 123: 263-270, 2003.
23. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC: Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer, 98: 119-127, 2003.
24. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S: Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int, 52: 19-24, 2002.
25. Lin F, Li Y, Cao J, Fan S, Wen J, Zhu G, Du H, Liang Y: Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells. Mol Biol Rep, 38: 5205-5210, 2011.
26. Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL, Ren WH: Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer, 130: 2685-2692, 2012.
27. Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E, Lee NP, Wu GH, Luk JM: Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol, 18: 3923-3930, 2012.
28. Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, Cui X, Ajioka Y, Hatakeyama K: Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol, 39: 1777-1783, 2008.
29. Weber SM, Lee FT, Jr: Expanded treatment of hepatic tumors with radiofrequency ablation and cryoablation. Oncology (Williston Park), 19: 27-32, 2005.
30. Kaibori M, Ishizaki M, Saito T, Matsui K, Kwon AH, Kamiyama Y: Risk factors and outcome of early recurrence after resection of small hepatocellular carcinomas. Am J Surg, 198: 39-45, 2009.
31. Wayne JD, Lauwers GY, Ikai I, Doherty DA, Belghiti J, Yamaoka Y, Regimbeau JM, Nagorney DM, Do KA, Ellis LM, Curley SA, Pollock RE, Vauthey JN: Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg, 235: 722-730, 2002.
32. Bruix J, Sherman M: Diagnosis of small HCC. Gastroenterology, 129: 1364, 2005.
33. Cui BK, Zhang CQ, Zhang Y, Yuan YF, Zhang YQ, Shi M, Chen MS, Li SP, Li JQ: Osteopontin as a potential biomarker of metastasis and recurrence for hepatocellular carcinoma. Ai Zheng, 25: 876-879, 2006.
34. Xie H, Song J, Du R, Liu K, Wang J, Tang H, Bai F, Liang J, Lin T, Liu J, Fan D: Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis, 39: 167-172, 2007.
35. Kim SH, Chung YH, Yang SH, Kim JA, Jang MK, Kim SE, Lee D, Lee SH, Lee D, Kim KM, Lim YS, Lee HC, Lee YS, Suh DJ: Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization. Korean J Hepatol, 15: 320-330, 2009.
36. Giannelli G, Fransvea E, Trerotoli P, Beaugrand M, Marinosci F, Lupo L, Nkontchou G, Dentico P, Antonaci S: Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta, 383: 147-152, 2007.
37. Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ: Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol, 23: 1541-1548, 2008.
38. Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire B: New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med, 45: 1169-1179, 2007.
39. Cho S, Ryu KM, Hwang YJ, Lee EB: Prognostic factors for pulmonary metastasectomy in the treatment of hepatocellular carcinoma. J Thorac Oncol, 5: 1251-1254, 2012.
40. Kitano K, Murayama T, Sakamoto M, Nagayama K, Ueno K, Murakawa T, Nakajima J: Outcome and survival analysis of pulmonary metastasectomy for hepatocellular carcinoma. Eur J Cardiothorac Surg, 41: 376-382, 2012.
41. Arrieta O, Cacho B, Morales-Espinosa D, Ruelas-Villavicencio A, Flores-Estrada D, Hernandez-Pedro N: The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer, 7: 28, 2007.
42. Kim J, Ki SS, Lee SD, Han CJ, Kim YC, Park SH, Cho SY, Hong YJ, Park HY, Lee M, Jung HH, Lee KH, Jeong SH: Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol, 101: 2051-2059, 2006.
43. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol, 35: 421-430, 2001.
44. Abu El Makarem MA, Abdel-Aleem A, Ali A, Saber R, Shatat M, Rahem DA, Sayed D: Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Ann Hepatol, 10: 296-305, 2011.
45. Christiansen M, Hogdall CK, Andersen JR, Norgaard-Pedersen B: Alpha-fetoprotein in plasma and serum of healthy adults: preanalytical, analytical and biological sources of variation and construction of age-dependent reference intervals. Scand J Clin Lab Invest, 61: 205-215, 2001.
46. Denhardt DT, Giachelli CM, Rittling SR: Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol, 41: 723-749, 2001.
47. Koguchi Y, Kawakami K, Uezu K, Fukushima K, Kon S, Maeda M, Nakamoto A, Owan I, Kuba M, Kudeken N, Azuma M, Yara S, Shinzato T, Higa F, Tateyama M, Kadota J, Mukae H, Kohno S, Uede T, Saito A: High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis. Am J Respir Crit Care Med, 167: 1355-1359, 2003.
48. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ: Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res, 9: 59-67, 2003.
49. Matsui A, Mochida S, Ohno A, Nagoshi S, Hirose T, Fujiwara K: Plasma osteopontin levels in patients with fulminant hepatitis. Hepatol Res, 29: 202-206, 2004.
50. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L: Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology, 55: 483-490, 2012.
51. Plumer A, Duan H, Subramaniam S, Lucas FL, Miesfeldt S, Ng AK, Liaw L: Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancer. BMC Cancer, 8: 38, 2008.
52. Constantinescu D, Vornicu M, Grigoriu C, Cozmei C, Grigoriu BD: Assaying for circulating osteopontin in practice: a technical note. Eur Respir J, 35: 1187-1188, 2010.
53. Vordermark D, Said HM, Katzer A, Kuhnt T, Hansgen G, Dunst J, Flentje M, Bache M: Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer, 6: 207, 2006.
54. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR: Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol, 6: 757-764, 2005.